“…• Reduction of natural killer cell activity (Sugimoto et al, 1999;Yokoyama et al, 2000) • Reduction of inflammatory cytokines IL-1, IL-4, IL-6, IL-8, TNF-α (Liu et al, 2013;Yang et al, 2015;Chen et al, 2018) • Increase of antiinflammatory cytokine IL-10 and of CGRP (Liu et al, 2013;Yang et al, 2015;Chen et al, 2018) Regulation of the endothelial dysfunction (Chen et al, 2012) Regulation of microcirculation and coagulopathy (Levy and Lorch, 1996;Hanamatsu et al, 2002;Pfister and Fischer, 2009;Yamazaki et al, 2012;Zhou et al, 2014;Punj, 2019) Reduction of (neurogenic) pulmonary edema (Pierach and Stotz, 1952;Zhang et al, 2013;Liu et al, 2017;Chen et al, 2018) Reduction of pulmonary arterial hypertension (Myers et al, 1998) Reduction of pathological positive feedback loops (Fischer, 2003;Jänig, 2011;Fischer, 2019) and has been favorably influenced by SGB in animal experiments (Chen et al, 2012). Leptin, released from adipocytes, also plays a role in arterial hypertension in collaboration with the SNS, and it causes endothelial dysfunction and increased blood pressure (Wang et al, 2013).…”